Home > Healthcare > Medical Devices > Diagnostic Devices > In-vitro Diagnostics Market

In-vitro Diagnostics Market Share

Report ID: GMI2820
Published Date: Mar 2023
Report Format: PDF

Download Free Sample

In-vitro Diagnostics Market Share

Abbott, BioMerieux SA
Becton
Dickinson
and Company, F. Hoffman - La Roche AG
Danaher Corporation
Sysmex Corporation
Thermo Fischer Scientific
DiaSorin
Bio-Rad Laboratories, Inc.
Ortho Clinical Diagnostics (QuidelOrtho),
Qiagen
and Siemens Healthineers

are some of the key participants involved in the market. These firms are engaging in production capacity expansion and portfolio diversification tactics to stay ahead in the competitive landscape.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Global market for in-vitro diagnostics recorded a valuation of more than USD 101 billion in 2022 and is primed to progress at a 3.5% CAGR between 2023 and 2032 propelled by surging incidences of chronic diseases such as blood pressure, other heart ailments, and lifestyle diseases globally.

Hematology segment is poised to grow at more than 4% CAGR from 2023 to 2032 as a result of their crucial role in the diagnosis and management of the COVID-19 illness.

In-vitro diagnostics market from infectious diseases application segment is anticipated to be valued at over USD 42 billion by 2032 owing to the demand for rapid diagnostic tests to identify and contain outbreaks.

North America market is slated to grow at more than 3% CAGR over 2023-2032 on account of escalating adoption of in-vitro diagnostics and supportive improvements in healthcare infrastructure in the region.